Esculentoside A(Synonyms: 商陆皂苷甲)

天然产物 糖类和糖苷 Saccharides and Glycosides

Esculentoside A (Synonyms: 商陆皂苷甲) 纯度: 98.27%

Esculentoside A (EsA),一种从商陆 Phytolacca esculenta 根部分离出来的三萜皂苷。 Esculentoside A (EsA) 在具有抗炎活性,对环氧合酶-2 (COX-2) 具有选择性抑制活性。 Esculentoside A (EsA) 通过抑制 (NF-ΚB) 和丝裂原活化蛋白激酶 (MAPK) 信号通路抑制 LPS 诱导的急性肺损伤 (ALI) 中的炎症反应。

Esculentoside A(Synonyms: 商陆皂苷甲)

Esculentoside A Chemical Structure

CAS No. : 65497-07-6

规格 价格 是否有货 数量
5 mg ¥800 In-stock
10 mg ¥1400 In-stock
20 mg ¥2300 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Esculentoside A 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Kinase Inhibitor Library
  • NF-κB Signaling Compound Library
  • Stem Cell Signaling Compound Library
  • Natural Product Library
  • Anti-Aging Compound Library
  • Antioxidants Compound Library
  • Differentiation Inducing Compound Library
  • Glycoside Compound Library
  • Oxygen Sensing Compound Library
  • Terpenoids Library
  • Pyroptosis Compound Library
  • Traditional Chinese Medicine Monomer Library
  • Anti-Breast Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Obesity Compound Library
  • Transcription Factor Targeted Library
  • Food-Sourced Compound Library
  • Anti-Liver Cancer Compound Library

生物活性

Esculentoside A (EsA), a kind of triterpene saponin isolated from roots of Phytolacca esculenta[1]. Esculentoside A (EsA) possesses anti-inflammatory activity in acute and chronic experimental models[2], has selective inhibitory activity towards cyclooxygenase-2 (COX-2)[1]. Esculentoside A (EsA) suppresses inflammatory responses in LPS-induced acute lung injury (ALI) through inhibition of the nuclear factor kappa B (NF-ΚB) and mitogen activated protein kinase (MAPK) signaling pathways[3].

体外研究
(In Vitro)

Esculentoside A (0-10 μM; 24 hours) reduced the release of TNF concentration in primed macrophages [4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Esculentoside A (EsA) (intraperitoneal injection; 20 mg/kg; once a day; 4 weeks) plays significant roles in the treatment of BXSB mice through modulation of inflammatory cytokines, inhibition of renal cell proliferation and induction of apoptosis [2].
Esculentoside A (EsA) (injected intraperitoneally; 5, 10 and 20 mg/kg; once a day; 7 days) dose-dependently decreases the TNF, IL-1 and IL-6 levels in the sera of mice following LPS challenge[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BXSB mice[2]
Dosage: 20 mg/kg
Administration: Intraperitoneal injection; 20 mg/kg; once a day; 4 weeks
Result: Alleviated the renal damage of LN.

分子量

826.96

Formula

C42H66O16

CAS 号

65497-07-6

中文名称

商陆皂苷甲

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (120.92 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.2092 mL 6.0462 mL 12.0925 mL
5 mM 0.2418 mL 1.2092 mL 2.4185 mL
10 mM 0.1209 mL 0.6046 mL 1.2092 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (3.02 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.02 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (3.02 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.02 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (3.02 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.02 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Wu F, et al. Synthesis, in vitro inhibitory activity towards COX-2 and haemolytic activity of derivatives of esculentoside A. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6430-3. Epub 2007 Oct 5.

    [2]. Ma H, et al. The effect of esculentoside A on lupus nephritis-prone BXSB mice. Arch Med Sci. 2013 Apr 20;9(2):354-60.

    [3]. Zhong WT, et al. Protective effect of esculentoside A on lipopolysaccharide-induced acute lung injury in mice. J Surg Res. 2013 Nov;185(1):364-72.

    [4]. Ju DW, et al. Esculentoside A inhibits tumor necrosis factor, interleukin-1, and interleukin-6 production induced by lipopolysaccharide in mice. Pharmacology. 1998 Apr;56(4):187-95

发表回复